» Articles » PMID: 33900852

Virilizing Doses of Testosterone Decrease Circulating Insulin Levels and Differentially Regulate Insulin Signaling in Liver and Adipose Tissue of Females

Abstract

Transgender men undergoing hormone therapy are at risk for insulin resistance. However, how virilizing testosterone therapy affects serum insulin and peripheral insulin sensitivity in transgender men is unknown. This study assessed the effect of acute, virilizing testosterone on serum insulin concentrations and insulin signaling in liver, skeletal muscle, and white adipose tissue (WAT) of female pigs as a translational model for transgender men. Females received three doses of intramuscular testosterone cypionate (TEST females; 50 mg/day/pig) or corn oil (control) spaced 6 days apart starting on the day of estrus (). Fasting blood was collected on , , , , and , and females were euthanized on . On , TEST females had virilizing concentrations of serum testosterone with normal concentrations of serum estradiol. Virilizing serum testosterone concentrations () were associated with decreased serum insulin and C-peptide concentrations. Blood glucose and serum glycerol concentrations were not altered by testosterone. Virilizing concentrations of testosterone downregulated and in subcutaneous (sc) WAT and upregulated transcript levels of insulin-signaling pathway components in WAT and liver. At the protein level, virilizing testosterone concentrations were associated with increased PI3K 110α in liver and increased insulin receptor (INSR) and phospho(Ser256)-FOXO1 in visceral (v) WAT but decreased phospho(Ser473)-AKT in vWAT and scWAT. These results suggest that acute exposure to virilizing concentrations of testosterone suppresses circulating insulin levels and results in increased abundance of proteins in the insulin-signaling pathway in liver and altered phosphorylation of key proteins in control of insulin sensitivity in WAT. Acute virilizing doses of testosterone administered to females suppress circulating insulin levels, upregulate components of the insulin-signaling pathway in liver, and suppress insulin signaling in white adipose tissue. These results suggest that insulin resistance in transgender men may be due to suppression of the insulin-signaling pathway and decreased insulin sensitivity in white adipose tissue.

Citing Articles

Reproductive Health in Trans and Gender Diverse Patients: Effects of transmasculine gender-affirming hormone therapy on future reproductive capacity: clinical data, animal models, and gaps in knowledge.

Chan-Sui R, Kruger R, Cho E, Padmanabhan V, Moravek M, Shikanov A Reproduction. 2024; 168(5).

PMID: 39190001 PMC: 11449632. DOI: 10.1530/REP-24-0163.


Challenges of prescribing testosterone for sexual dysfunction in women: Number 7 - 2024.

Lara L, Pereira J, de Paula S, de Oliveira F, Cunha A, Lerner T Rev Bras Ginecol Obstet. 2024; 46.

PMID: 39176198 PMC: 11341187. DOI: 10.61622/rbgo/2024FPS07.


Fabrication of silastic testosterone enanthate implants to achieve virilizing levels of serum testosterone in swine.

Mahabir N, Newell-Fugate A MethodsX. 2024; 12:102549.

PMID: 38283761 PMC: 10820632. DOI: 10.1016/j.mex.2024.102549.


The Utility of Preclinical Models in Understanding the Bone Health of Transgender Individuals Undergoing Gender-Affirming Hormone Therapy.

Venkatesh V, Nie T, Zajac J, Grossmann M, Davey R Curr Osteoporos Rep. 2023; 21(6):825-841.

PMID: 37707757 PMC: 10724092. DOI: 10.1007/s11914-023-00818-2.


Rodent Model of Gender-Affirming Hormone Therapies as Specific Tool for Identifying Susceptibility and Vulnerability of Transgender People and Future Applications for Risk Assessment.

Tassinari R, Maranghi F Int J Environ Res Public Health. 2021; 18(23).

PMID: 34886364 PMC: 8656759. DOI: 10.3390/ijerph182312640.

References
1.
Unger C . Hormone therapy for transgender patients. Transl Androl Urol. 2017; 5(6):877-884. PMC: 5182227. DOI: 10.21037/tau.2016.09.04. View

2.
Zhou Z, Ribas V, Rajbhandari P, Drew B, Moore T, Fluitt A . Estrogen receptor α protects pancreatic β-cells from apoptosis by preserving mitochondrial function and suppressing endoplasmic reticulum stress. J Biol Chem. 2018; 293(13):4735-4751. PMC: 5880140. DOI: 10.1074/jbc.M117.805069. View

3.
Lin H, Yu I, Wang R, Chen Y, Liu N, Altuwaijri S . Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. Hepatology. 2008; 47(6):1924-35. DOI: 10.1002/hep.22252. View

4.
Varlamov O, White A, Carroll J, Bethea C, Reddy A, Slayden O . Androgen effects on adipose tissue architecture and function in nonhuman primates. Endocrinology. 2012; 153(7):3100-10. PMC: 3380299. DOI: 10.1210/en.2011-2111. View

5.
Fernandez J, Tannock L . METABOLIC EFFECTS OF HORMONE THERAPY IN TRANSGENDER PATIENTS. Endocr Pract. 2015; 22(4):383-8. PMC: 4824309. DOI: 10.4158/EP15950.OR. View